TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15280971

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic hemoclip placement (EHP)
Number of subjects: 26
Study: 10954886

Group type: EXPERIMENTAL
Intervention: nevirapine plus ritonavir
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: lamivudine plus nelfinavir
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: nevirapine plus nelfinavir
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: lamivudine plus nevirapine plus nelfinavir
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: stavudine plus lamivudine plus nelfinavir (bid)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: stavudine plus lamivudine plus nelfinavir (tid)
Number of subjects: 181
Study: 9327686

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 199

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 199
Study: 8350329

Group type: EXPERIMENTAL
Intervention: Leucovorin (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2871058

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.4 mg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 7
Study: 31731885

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 12
Study: 30507229

Group type: EXPERIMENTAL
Intervention: Computer-based evaluative conditioning intervention consisting of six online training sessions of 5 minutes each, where participants clicked on pictures of their own and other people's bodies, with their own pictures followed by portraits of friendly smiling faces.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo-control condition where participants were shown the same stimuli, but their own body was not paired with smiling faces.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Computer-based evaluative conditioning intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo-control condition
Number of subjects: 51
Study: 27000036

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (eight weekly sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Relaxation therapy (eight weekly sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 45
Study: 24119199

Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21917048

Group type: EXPERIMENTAL
Intervention: Applied behaviour analysis (ABA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 19419253

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor and diuretic combination
Number of subjects: 0
Study: 17713154

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) combined with emtricitabine (ADV/FTC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 15141745

Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifampicin from local manufacturer 3
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rifampicin from international manufacturer
Number of subjects: 12
Study: 12521783

Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400
Study: 10198499

Group type: EXPERIMENTAL
Intervention: Eating everything one liked and drinking more (intervention group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fasting for 24 hours with specified limitations (control group)
Number of subjects: 71
Study: 7870011

Group type: EXPERIMENTAL
Intervention: HuEPO treatment for anemia in preterm infants
Number of subjects: 0
Study: 3276112

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study: 6992229

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long acting progesterone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antispasmodic
Number of subjects: 100
Study: 28856932

Group type: EXPERIMENTAL
Intervention: Cogmed training (working memory training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (low-intensity comparison version of the training)
Number of subjects: 0
Study: 30392080

Group type: EXPERIMENTAL
Intervention: aPDT adjunct to SRP
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study: 28526551

Group type: EXPERIMENTAL
Intervention: Inlay block xenograft (sandwich osteotomy) fixed with mini‐plates
Number of subjects: 16

Group type: COMPARATOR
Intervention: Onlay particulate xenograft with titanium mesh
Number of subjects: 16
Study: 25415767

Group type: EXPERIMENTAL
Intervention: Active product (high-molecular-weight hyaluronan)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 22797530

Group type: EXPERIMENTAL
Intervention: Clearfil AP‐X (hybrid composite)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Filtek Z350 (nanocomposite)
Number of subjects: 46
Study: 21896619

Group type: EXPERIMENTAL
Intervention: Licorice
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ordinary treatment (Control)
Number of subjects: 17
Study: 19500606

Group type: EXPERIMENTAL
Intervention: Amusic group (n=32)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-amusic group (n=21)
Number of subjects: 53
Study: 17560080

Group type: EXPERIMENTAL
Intervention: Weight-loss group (dietary weight-loss program: high-fruit/vegetable and low-fat dairy diet or low-fat diet)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Weight-loss group
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-fruit/vegetable and low-fat dairy diet group (n = 14)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 15369941

Group type: EXPERIMENTAL
Intervention: Pinch technique before and during DMPA injection
Number of subjects: 78

Group type: COMPARATOR
Intervention: Injection only (control group)
Number of subjects: 78
Study: 11600531

Group type: EXPERIMENTAL
Intervention: Tibolone 0.3 mg daily
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tibolone 0.625 mg daily
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg daily
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770
Study: 9682807

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 10

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 10
Study: 7914564

Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 1301
Study: 2459988

Group type: EXPERIMENTAL
Intervention: Atracurium (dosage not specified)
Number of subjects: 0
Study: 241119

Group type: EXPERIMENTAL
Intervention: Oral erythromycin stearate (500 mg twice or 3 times a day for 10 days)
Number of subjects: 76
Study: 31284175

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28597081

Group type: COMPARATOR
Intervention: Bright light (BRIGHT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Monochromatic blue light (BLUE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Control condition (CONTROL)
Number of subjects: 72
Study: 26144593

Group type: EXPERIMENTAL
Intervention: Low (2.9%)-THC vaporized cannabis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High (6.7%)-THC vaporized cannabis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alcohol (0.05g/210L and 0.08g/210L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cannabis-alcohol combination (5μg/L THC + 0.05g/210L alcohol)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23460688

Group type: EXPERIMENTAL
Intervention: Parent-focused intervention (six 2-hour dietitian-delivered sessions over 15 months)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control group (6 newsletters on nonobesity-focused themes)
Number of subjects: 542
Study: 21401541

Group type: EXPERIMENTAL
Intervention: Ocular compression using an external pressure device for 20 min before combined peri- and retrobulbar injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with pressure applied only after the block was completed
Number of subjects: 60
Study: 19336453

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice a day) plus optimized background therapy (OBT)
Number of subjects: 51
Study: 17353499

Group type: EXPERIMENTAL
Intervention: High-fiber DASH diet (30 g/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fiber-supplemented diet (30 g/d)
Number of subjects: 35
Study: 15115860

Group type: COMPARATOR
Intervention: Eotaxin 20 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eotaxin 40 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eotaxin 5, 10, and 20 microg
Number of subjects: 16
Study: 11482684

Group type: EXPERIMENTAL
Intervention: Cetirizine and cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diphenhydramine and placebo
Number of subjects: 0
Study: 9505883

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 12
Study: 8172146

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. (group II; n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 3370890

Group type: EXPERIMENTAL
Intervention: Straight catheterization in the recovery room
Number of subjects: 54

Group type: COMPARATOR
Intervention: Not straight catheterized (control group)
Number of subjects: 54
Study: 31661579

Group type: EXPERIMENTAL
Intervention: Standard treatment with 12 weeks of education (I-group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard treatment (C-group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (I-group and C-group)
Number of subjects: 98
Study: 29622380

Group type: EXPERIMENTAL
Intervention: Tralokinumab 150 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tralokinumab 600 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tralokinumab (150, 300, or 600 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg)
Number of subjects: 30
Study: 28258661

Group type: EXPERIMENTAL
Intervention: G-CEM LinkAceTM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: BisCem®
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Maxcem EliteTM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lithium disilicate
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Zirconia and lithium disilicate
Number of subjects: 3
Study: 25328082

Group type: EXPERIMENTAL
Intervention: G. kola 12.5 g once daily for 7 days (group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G. kola 12.5 g twice daily for 6 days and once on the seventh day (group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quinine with G. kola
Number of subjects: 24
Study: 24211339

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverse Attention Bias Modification (inverse ABM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 21553071

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sandblaster
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser/sandblaster
Number of subjects: 76

Group type: COMPARATOR
Intervention: Untreated (Control Group 1)
Number of subjects: 76
Study: 18440385

Group type: EXPERIMENTAL
Intervention: UT‐EGD method
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 28
Study: 17968657

Group type: EXPERIMENTAL
Intervention: Youth Matters prevention curriculum
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 28
Study: 12950483

Group type: EXPERIMENTAL
Intervention: Triage-based e-mail system
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no access to e-mail system)
Number of subjects: 2
Study: 11009233

Group type: EXPERIMENTAL
Intervention: 0.5% intrathecal ropivacaine (ROP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5% intrathecal bupivacaine (BUP)
Number of subjects: 12
Study: 8695028

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: bendrofluazide
Number of subjects: 37
Study: 1587589

Group type: EXPERIMENTAL
Intervention: EcSf2a-1 vaccine (1.0 x 10(9) CFU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.5 x 10(11) CFU in three doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (2.5 x 10(9) CFU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.8 x 10(10) CFU)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (1.2 to 2.5 x 10(9) CFU in three doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine
Number of subjects: 13

Group type: COMPARATOR
Intervention: E. coli K-12 placebo
Number of subjects: 13
Study: 4029558

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (94%)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glucose polymers
Number of subjects: 11
Study: 29119275

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study: 26393389

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 1061
Study: 24849793

Group type: EXPERIMENTAL
Intervention: Wii Sports Resort training plus usual therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 62
Study: 22138200

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral intervention delivered by telephone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 196
Study: 20383504

Group type: EXPERIMENTAL
Intervention: Posaconazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole prophylaxis
Number of subjects: 0
Study: 19192438

Group type: EXPERIMENTAL
Intervention: Doxepin 1 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxepin 3 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15758622

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 3 mg enema once daily for 6 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: 5-ASA (mesalamine) 1 g enema daily for 6 weeks
Number of subjects: 217
Study: 12091296

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10323605

Group type: EXPERIMENTAL
Intervention: HGH (0.1 mg/kg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HGH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 8759894

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) (8 mg/m2, i.v., days 1-5)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Zorubicin (ZRB) (200 mg/m2, i.v., days 1-4)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Consolidation therapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 251
Study: 1929586

Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 0
Study: 6352185

Group type: EXPERIMENTAL
Intervention: Indapamide 1.0 mg/day for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indapamide 5.0 mg/day for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indapamide (all doses)
Number of subjects: 10
Study: 31498145

Group type: EXPERIMENTAL
Intervention: Game-based hand resistance exercise (30 min/day, 5 days/week, for 6 weeks with 70% of the 1-repetition maximum)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional manual exercise by occupational therapist (same duration and frequency as experimental group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Game-based hand resistance exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional manual exercise
Number of subjects: 50
Study: 29174926

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 26909960

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii pills (orally administered) for three courses of treatment, each consisting of 4 weeks, in addition to conventional western medicine.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional western medicine (control group).
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (observation and control).
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Observation group (T. wilfordii + conventional medicine).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (conventional medicine).
Number of subjects: 82
Study: 24658769

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 779

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 779
Study: 22382219

Group type: EXPERIMENTAL
Intervention: Normal saline (0.9%) hydration at 1 mL/kg/h for 12 hours before and 24 hours after PCI
Number of subjects: 240
Study: 20801446

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplementation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 17096666

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg/ml intravenously every 6 h during the first post-operative day (total, 400 mg/24 h)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 63
Study: 15846274

Group type: EXPERIMENTAL
Intervention: Carbon ion-implanted Arthos Inert stent (group 1)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Bare metal Arthos stent (group 2)
Number of subjects: 225
Study: 11827256

Group type: EXPERIMENTAL
Intervention: Er‐YAG laser irradiation at 2 Hz and 180 mJ with water‐cooling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acid‐etching with 35% H3PO4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser‐ and acid‐etched
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acid‐etching alone
Number of subjects: 0
Study: 10422481

Group type: EXPERIMENTAL
Intervention: Eight-session psychoeducational programme for patients with schizophrenia and their relatives
Number of subjects: 0
Study: 7776163

Group type: EXPERIMENTAL
Intervention: Hand toothbrush
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Automatic toothbrush 1
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Automatic toothbrush 2
Number of subjects: 58

Group type: COMPARATOR
Intervention: No brushing (control)
Number of subjects: 58
Study: 2104438

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of sodium heparin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of sodium heparin
Number of subjects: 94
Study: 697222

Group type: EXPERIMENTAL
Intervention: Smoking marihuana cigarettes containing 6 mg of delta‐9‐tetrahydrocannabinol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 14
Study: 30802822

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 80 mg/m2 (first cycle at 60 mg/m2, escalated to 80 mg/m2 in the absence of grade 3/4 toxicity)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Intravenous paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Intravenous paclitaxel
Number of subjects: 131
Study: 28389572

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 9102

Group type: COMPARATOR
Intervention: Functional testing (exercise electrocardiography, nuclear stress, or stress echocardiography)
Number of subjects: 9102

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 9102

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 9102

Group type: EXPERIMENTAL
Intervention: Reclassification of 2714 patients with normal functional test as mildly abnormal
Number of subjects: 9102
Study: 26218258

Group type: EXPERIMENTAL
Intervention: Follow-up clinic (intervention)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 209